



**ALPHA IVF GROUP BERHAD**

202101005100 (1405399-X)

**ALPHA IVF GROUP BERHAD  
AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED  
INTERIM FINANCIAL REPORT  
FOR THE FIRST QUARTER ENDED  
31 AUGUST 2025**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FIRST QUARTER ENDED 31 AUGUST 2025**

	Note	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
		31.8.2025 RM'000	31.8.2024 RM'000	31.8.2025 RM'000	31.8.2024 RM'000
<b>Revenue</b>	<b>A9</b>	<b>52,095</b>	<b>42,995</b>	<b>52,095</b>	<b>42,995</b>
Cost of sales		(20,617)	(17,317)	(20,617)	(17,317)
<b>Gross profit</b>		<b>31,478</b>	<b>25,678</b>	<b>31,478</b>	<b>25,678</b>
Other income		2,004	1,596	2,004	1,596
Administrative expenses		(10,214)	(7,507)	(10,214)	(7,507)
Other expenses		(1,870)	(511)	(1,870)	(511)
Finance costs		(414)	(256)	(414)	(256)
<b>Profit before taxation ("PBT")</b>	<b>B12</b>	<b>20,984</b>	<b>19,000</b>	<b>20,984</b>	<b>19,000</b>
Income tax expense	<b>B6</b>	(5,613)	(4,057)	(5,613)	(4,057)
<b>Profit after taxation ("PAT")</b>		<b>15,371</b>	<b>14,943</b>	<b>15,371</b>	<b>14,943</b>
<b>Other comprehensive income</b>					
<u>Item that will be reclassified subsequently to profit or loss</u>					
Foreign currency translation differences		(355)	(423)	(355)	(423)
<b>Total comprehensive income</b>		<b>15,016</b>	<b>14,520</b>	<b>15,016</b>	<b>14,520</b>
<b>Profit after taxation attributable to:</b>					
Owners of the Company		15,280	14,381	15,280	14,381
Non-controlling interests		91	562	91	562
		<b>15,371</b>	<b>14,943</b>	<b>15,371</b>	<b>14,943</b>
<b>Total comprehensive income attributable to:</b>					
Owners of the Company		14,954	14,057	14,954	14,057
Non-controlling interests		62	463	62	463
		<b>15,016</b>	<b>14,520</b>	<b>15,016</b>	<b>14,520</b>
<b>Earnings per share attributable to Owners of the Company</b>					
Basic/Diluted (sen) <sup>(1)</sup>	<b>B11</b>	<b>0.31</b>	<b>0.30</b>	<b>0.31</b>	<b>0.30</b>

**Note:**

(1) The basic and diluted earnings per share of the Company are computed based on PAT attributable to the Owners of the Company divided by the number of ordinary shares of the Company referred to in Note B11. The Group has not issued any dilutive potential ordinary shares and hence, the diluted earnings per share is equal to the basic earnings per share.

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

**ALPHA IVF GROUP BERHAD**

Registration No.: 202101005100 (1405399-X)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 31 AUGUST 2025**

	<b>Unaudited</b>	<b>Audited</b>
	<b>As at</b>	<b>As at</b>
	<b>31.8.2025</b>	<b>31.5.2025</b>
	<b>RM'000</b>	<b>RM'000</b>
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
Equipment	14,787	13,767
Right-of-use assets	28,249	22,425
Other investments	30,520	30,563
Goodwill	8,931	8,931
Deferred tax assets	1,702	1,702
	<b>84,189</b>	<b>77,388</b>
<b>Current Assets</b>		
Inventories	4,349	2,817
Trade receivables	3,007	1,590
Other receivables, deposits and prepayments	18,043	13,127
Current tax asset	227	5
Short-term investments	106,214	121,449
Fixed deposits with licensed banks	4,048	-
Cash and bank balances	30,136	34,432
	<b>166,024</b>	<b>173,420</b>
<b>TOTAL ASSETS</b>	<b>250,213</b>	<b>250,808</b>
<b>EQUITY AND LIABILITIES</b>		
Share capital	119,753	119,753
Retained profits	46,951	55,971
Reorganisation reserve	22,499	22,499
Foreign exchange translation reserve	(511)	(185)
Equity attributable to Owners of the Company	<b>188,692</b>	<b>198,038</b>
Non-controlling interests	6,273	6,109
<b>Total Equity</b>	<b>194,965</b>	<b>204,147</b>
<b>Non-Current Liabilities</b>		
Lease liabilities	24,570	21,659
Provision for restoration costs	1,256	1,227
	<b>25,826</b>	<b>22,886</b>
<b>Current Liabilities</b>		
Trade payables	1,595	2,808
Other payables and accruals	6,789	5,701
Contract liabilities	9,015	8,329
Lease liabilities	5,065	1,848
Current tax liabilities	6,958	5,089
	<b>29,422</b>	<b>23,775</b>
<b>Total Liabilities</b>	<b>55,248</b>	<b>46,661</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>250,213</b>	<b>250,808</b>
<b>Net assets per ordinary share attributable to Owners of the Company (RM)</b>	<b>0.04</b>	<b>0.04</b>

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

**ALPHA IVF GROUP BERHAD**  
**Registration No.: 202101005100 (1405399-X)**  
(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
FOR THE FIRST QUARTER ENDED 31 AUGUST 2025**

	Share Capital	Reorganisation Reserve	Foreign Exchange Translation Reserve	Retained Profits	Attributable to Owners of the Company	Non- Controlling Interests	Total Equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
<b>As at 1 June 2025</b>	119,753	22,499	(185)	55,971	198,038	6,109	204,147
Profit after taxation for the financial period	-	-	-	15,280	15,280	91	15,371
Other comprehensive expenses for the financial period: - Foreign currency translation differences	-	-	(326)	-	(326)	(29)	(355)
Total comprehensive (expenses)/income for the financial period	-	-	(326)	15,280	14,954	62	15,016
Dividend by the Company	-	-	-	(24,300)	(24,300)	-	(24,300)
Ordinary share capital contributed by non-controlling interests of a subsidiary	-	-	-	-	-	102	102
<b>As at 31 August 2025</b>	<b>119,753</b>	<b>22,499</b>	<b>(511)</b>	<b>46,951</b>	<b>188,692</b>	<b>6,273</b>	<b>194,965</b>

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE FIRST QUARTER ENDED 31 AUGUST 2025**

	<u>Period Ended</u> <b>31.8.2025</b> RM'000	<u>Period Ended</u> <b>31.8.2024</b> RM'000
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before taxation	20,984	19,000
Adjustments for:		
Depreciation of equipment	932	600
Depreciation of right-of-use assets	1,188	692
Interest expenses	414	256
Equipment written off	5	-
(Gain)/Loss on disposal of equipment	(36)	#
Fair value gain on unit trust funds	(44)	-
Dividend income from a short-term investment	(2)	-
Unrealised loss on foreign exchange	560	-
Interest income	(1,283)	(1,524)
Operating profit before working capital changes	<u>22,718</u>	<u>19,024</u>
Changes in working capital:		
Inventories	(1,534)	(326)
Trade and other receivables	(6,034)	(80)
Trade and other payables	(603)	1,102
Contract liabilities	687	375
<b>CASH FROM OPERATIONS</b>	<u>15,234</u>	<u>20,095</u>
Income tax paid	(3,967)	(2,646)
<b>NET CASH FROM OPERATING ACTIVITIES</b>	<u>11,267</u>	<u>17,449</u>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>		
Proceeds from disposal of equipment	127	-
Dividend income from a short-term investment	2	-
Interest income	897	1,524
Purchase of equipment	(2,075)	(822)
Withdrawal/(Placement) of short-term investments	14,397	(4,304)
<b>NET CASH FROM/(FOR) INVESTING ACTIVITIES</b>	<u>13,348</u>	<u>(3,602)</u>
<b>CASH FLOW FOR FINANCING ACTIVITIES</b>		
Dividend paid by the Company	(24,300)	(21,870)
Proceeds from issuance of share capital to non-controlling interests by a subsidiary	102	-
Interest paid	(362)	(179)
Repayment of lease liabilities	(867)	(653)
<b>NET CASH FOR FINANCING ACTIVITIES</b>	<u>(25,427)</u>	<u>(22,702)</u>
<b>Net decrease in cash and cash equivalents</b>	(812)	(8,855)
<b>Effect of foreign exchange translation</b>	(322)	(570)
<b>Cash and cash equivalents at beginning of the financial period</b>	<u>133,424</u>	<u>92,178</u>
<b>Cash and cash equivalents at end of the financial period</b>	<u>132,290</u>	<u>82,753</u>
<b>Note:</b>		
<u>Cash and cash equivalents comprise of the following:</u>		
Short-term investments - money market funds	98,106	69,946
Fixed deposits with licensed banks	4,048	-
Cash and bank balances	30,136	12,807
	<u>132,290</u>	<u>82,753</u>

# – Less than RM1,000.

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 and the accompanying explanatory notes attached to this interim financial report.

**A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 AUGUST 2025**

**A1. Basis of Preparation**

The interim financial report of Alpha IVF Group Berhad (“Company”) and its subsidiaries (“Group”) are unaudited and have been prepared in accordance with requirements of Malaysian Financial Reporting Standards (“MFRS”) No. 134: Interim Financial Reporting and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements (“Listing Requirements”) of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements for the financial year ended 31 May 2025 as disclosed in the Annual Report 2025 and the accompanying notes attached to this interim financial report.

**A2. Summary of Significant Accounting Policies**

The significant accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted in the most recent audited annual financial statements for the year ended 31 May 2025. During the current financial year, the Group has adopted the following new accounting standards and/or interpretations (including the consequential amendments, if any):

<b>MFRSs and/or IC Interpretations (Including the Consequential Amendments)</b>	<b>Effective Date</b>
Amendments to MFRS 121: Lack of Exchangeability	1 January 2025

The adoption of the above accounting standards and/or interpretations (including the consequential amendments, if any) did not have any material impact on the Group’s financial statements.

The Group has not applied in advance the following accounting standards and/or interpretations (including the consequential amendments, if any) that have been issued by the Malaysian Accounting Standard Board (“MASB”) but are not yet effective for the financial period ended 31 August 2025:

<b>MFRSs and/or IC Interpretations (Including the Consequential Amendments)</b>	<b>Effective Date</b>
Annual Improvements to MFRS Accounting Standards – Volume 11	1 January 2026
Amendments to MFRS 9 and MFRS 7: Amendments to the Classification and Measurement of Financial Instruments	1 January 2026
Amendments to MFRS 9 and MFRS 7: Contracts Referencing Nature-dependent Electricity	1 January 2026
MFRS 18: Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19: Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred

The Group is in process of assessing the impact of implementing the above accounting standards and/or interpretations in the year of initial application.

**A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 AUGUST 2025 (CONT'D)**

**A3. Auditors' Report on preceding Annual Financial Statements**

There was no qualification on the audited consolidated financial statements of the Group for the financial year ended 31 May 2025.

**A4. Seasonal or cyclical factors**

The business operation of the Group has not been materially affected by any unusual seasonal or cyclical factors.

**A5. Unusual items affecting assets, liabilities, equity, net income or cash flows**

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and financial year-to-date.

**A6. Material changes in estimates**

There were no material changes in estimates that have a material effect to the Group in the current financial quarter and financial year-to-date.

**A7. Debt and equity securities**

There were no issuance, cancellation, repurchase, resale and repayment of debt and equity securities during the current financial quarter under review.

**A8. Dividends Paid**

The Company declared a second single-tier interim dividend of 0.50 sen per ordinary share on 4,860,000,000 shares amounting to RM24,300,000 on 28 July 2025 in respect of the financial year ended 31 May 2025, which was paid on 29 August 2025, to shareholders whose names appeared in the Company's Register of Members and/or record of depositors on 11 August 2025.

The total dividends of RM24,300,000 declared and paid is accounted for in equity as an appropriation of retained profits for the financial year ending 31 May 2026.

**A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 AUGUST 2025 (CONT'D)**

**A9. Segmental Reporting**

The Group operates predominantly in one business segment i.e. focused only in the business of operating women's specialists centres and provision of medical consultants and specialised medical services. Accordingly, the information by business segments is not presented.

**Geographical Market**

The following table provides an analysis of the Group's revenue by geographical segment:

	<u>CURRENT QUARTER ENDED</u>		<u>CUMULATIVE PERIOD ENDED</u>	
	31.8.2025	31.8.2024	31.8.2025	31.8.2024
	RM'000	RM'000	RM'000	RM'000
Revenue				
- Malaysia	47,946	35,403	47,946	35,403
- Singapore	3,908	7,592	3,908	7,592
- Indonesia*	241	-	241	-
	<u>52,095</u>	<u>42,995</u>	<u>52,095</u>	<u>42,995</u>

\*The Group commenced its Indonesia operations on 5 May 2025.

**A10. Valuation of Equipment**

There was no valuation of equipment in the current financial quarter under review.

**A11. Material events subsequent to the end of the current financial quarter**

Save as disclose below, there are no material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

**(a) Land Lease Agreement ("LLA") between PT Hotel Indonesia Natour ("HIN") and PT Alpha IVF Dan SPOG Bali ("ASPOBA") and Sponsor Support Agreement ("SSA") between HIN, Alpha IVF Systems Sdn. Bhd. ("AIS"), PT Delemont Global Venture ("PT Delemont"), Alpha IVF Group Berhad ("Alpha IVF"), ASPOBA and Thomas Irawan Tjahjono**

On 30 September 2025, ASPOBA, a 75%-owned subsidiary of AIS, had entered into the following Agreements:

- (i) LLA with HIN for the lease of a parcel of land within Sanur Special Economic Zone in Bali, Indonesia; and
- (ii) SSA between HIN, AIS, PT Delemont, Alpha IVF, ASPOBA and Thomas Irawan Tjahjono to record the undertakings of the Sponsors to provide financial and operational support to ASPOBA so that ASPOBA is able to meet its obligations under the LLA entered into with HIN.

**A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 AUGUST 2025 (CONT'D)**

**A12. Changes in the composition of the Group**

Save as disclose below, there were no changes in the composition of the Group during the current financial quarter under review and subsequent to the end of the current financial quarter.

**(i) During current financial quarter**

**(a) Increase of Issued and Paid-Up Capital of Alpha International Women's Specialists (Johor) Sdn. Bhd. ("AIWSJ")**

On 17 June 2025, AIWSJ, a wholly-owned subsidiary of the Company, increased its issued and paid-up capital from RM201,000 to RM701,000 by the issuance of 500,000 new ordinary shares. The Company subscribed for the additional 500,000 ordinary shares at RM1 each.

**(b) Incorporation of Alpha IVF (Tuguegarao) Incorporation ("AITI")**

On 18 July 2025, AIS, a wholly-owned subsidiary of the Company, has incorporated a 89%-owned subsidiary, AITI, with authorised capital of Philippine peso ("PHP") 137,000,000 (equivalent to RM10,164,167) comprising 137,000,000 ordinary shares. AIS subscribed for 121,903,000 (included 27,400 ordinary shares held in trust by the Directors of the Company) new ordinary shares at PHP121,930,000 (equivalent to RM830,494).

**(c) Incorporation of ASPOBA**

On 18 July 2025, AIS has incorporated a 75%-owned subsidiary, ASPOBA, with an authorised capital of IDR100,000,000,000 (approximately RM25,900,000) and issued and paid-up capital of IDR38,000,000,000 (approximately RM9,842,000) respectively. AIS subscribed for 2,850,000 paid-up capital at IDR28,500,000,000 (equivalent to RM7,350,324).

**(d) Increase of Issued and Paid-Up Capital of Alpha International (Shanghai) Medical Consulting Limited ("AISMC")**

On 26 August 2025, AISMC, an indirect subsidiary of the Company, increased its issued and paid-up capital from RM625,660 to RM861,896 by the issuance of 397,811 new ordinary shares at Chinese Yuan ("CNY") 1 (approximately RM0.5938). The Company subscribed for the additional 397,811 ordinary shares at RM0.5938 each.

**(e) Increase of Issued and Paid-Up Capital of Alpha International (Guangzhou) Medical Consulting Limited ("AIGMC")**

On 26 August 2025, AIGMC, an indirect subsidiary of the Company, increased its issued and paid-up capital from RM348,777 to RM390,962 by the issuance of 70,915 new ordinary shares at CNY1 (approximately RM0.5949) each. The Company subscribed for the additional 70,915 ordinary shares at RM0.5949 each.

**A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 AUGUST 2025 (CONT'D)**

**A12. Changes in the composition of the Group (Cont'd)**

Save as disclose below, there were no changes in the composition of the Group during the current financial quarter under review and subsequent to the end of the current financial quarter. (Cont'd)

**(ii) Subsequent to the current financial quarter**

**(a) Increase of Issued and Paid-Up Capital of AIGMC**

On 12 September 2025, AIGMC, an indirect subsidiary of the Company, increased its issued and paid-up capital from RM390,962 to RM521,240 by the issuance of 220,027 new ordinary shares at CNY 1 (approximately RM0.5921) each. The Company subscribed for the additional 220,027 ordinary shares at RM0.5921 each.

**(b) Increase of Issued and Paid-Up Capital of AIS**

On 25 September 2025, AIS, a wholly-owned subsidiary of the Company, increased its issued and paid-up capital from RM24,700,000 to RM30,700,000 by the issuance of 6,000,000 new ordinary shares. The Company subscribed for the additional 6,000,000 ordinary shares at RM1 each.

**A13. Contingent Assets and Contingent Liabilities**

There were no contingent assets and contingent liabilities as at the date of this interim financial report.

**A14. Material capital commitments**

Save as disclosed below, there is no material commitment for capital expenditure, which upon becoming enforceable, may have a material effect on the Group's financial position as at the date of this interim financial report.

	31.8.2025	31.5.2025
	RM'000	RM'000
Purchase of equipment	<u>12,195</u>	<u>12,615</u>

**(THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK)**

**A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 31 AUGUST 2025 (CONT'D)**

**A15. Significant related party transactions**

The Group carried out the following significant transactions with related parties during the financial period:

Transacting Parties	Nature of transactions	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
		31.8.2025 RM'000	31.8.2024 RM'000	31.8.2025 RM'000	31.8.2024 RM'000
<u>Significant transactions with Directors of the Company</u>					
(i) AIWS and Dato' Dr. Lee Soon Soo ("DDLSS")	Consultancy services provided by DDLSS	(380)	(299)	(380)	(299)
(ii) Genesis and Dr. Ng Peng Wah ("DNPW")	Consultancy services provided by DNPW	(791)	(747)	(791)	(747)
<u>Significant transactions with Directors of the Subsidiaries</u>					
(iii) AIWS and Dr. Haris Bin Hamzah ("Dr. Haris")	Consultancy services provided by Dr. Haris	(69)	(36)	(69)	(36)
(iv) Alhaya and Dr. Haris	Consultancy services provided by Dr. Haris	(36)	(63)	(36)	(63)
<u>Significant transactions with Related Parties</u>					
(v) AIWSS and Dr. Tan Heng Hao ("Dr. Tan")	Consultancy services provided by Dr. Tan	(46)	(1,600)	(46)	(1,600)
(vi) AIWSS and Dr. Tan	Administrative fee income charged to Dr. Tan	-	-	-	-
(vii) AIWS and Baby Xort Sdn. Bhd. ("Baby Xort")	Sperm sorting services provided by Baby Xort	(183)	(116)	(183)	(116)
(viii) Alhaya and Baby Xort	Sperm sorting services provided by Baby Xort	(7)	-	(7)	-

AIWS – Alpha International Women's Specialists Sdn. Bhd.  
AIWSS – Alpha International Women's Specialists (Singapore) Pte. Ltd.  
Genesis – Genesis Specialists Sdn. Bhd.  
Alhaya – Alhaya International Women's Specialists Sdn. Bhd.

**B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF  
BURSA MALAYSIA SECURITIES BERHAD**

**B1. Review of Performance**

**(a) Results for current quarter**

The Group recorded a revenue of RM52.10 million for the current financial quarter ended 31 August 2025 which represented an increase of RM9.10 million or 21.16% as compared to the recorded revenue of RM43.00 million for the preceding year corresponding quarter ended 31 August 2024. The revenue increased primarily due to the higher sales from local and foreign patients to the Malaysia operations. The Group's revenue was principally derived from the provision of assisted reproductive services focusing on in-vitro fertilisation ("IVF") treatments.

The Group recognised a PBT of RM20.98 million and PAT of RM15.37 million for the current financial quarter compared to PBT of RM19.00 million and PAT of RM14.94 million for the preceding year corresponding quarter ended 31 August 2024. The increase in PBT by RM1.98 million or 10.42% and PAT by RM0.43 million or 2.88% was primarily driven by higher sales and improved profit margin, reflecting the benefits of greater economies of scale from our Malaysia operations.

**(b) Results for financial year-to-date**

The Group recorded a revenue of RM52.10 million for the current financial year ended 31 August 2025 which represented an increase of RM9.10 million or 21.16% as compared to RM43.00 million in the preceding corresponding year ended 31 August 2024. The increase was primarily attributable to higher sales from local and foreign patients to the Malaysia operations. The Group's revenue was principally derived from the provision of assisted reproductive services focusing on IVF treatments.

The Group recognised a PBT of RM20.98 million and PAT of RM15.37 million for the current financial year, representing an increase of RM1.98 million or 10.42% in PBT and RM0.43 million or 2.88% in PAT as compared to the preceding corresponding year ended 31 August 2024. The increase in PBT and PAT were mainly attributed to the higher sales and the improved profit margin, reflecting the benefits of greater economies of scale from our Malaysia operations.

**B2. Comparison with immediate preceding quarter's results**

On a quarter-on-quarter basis, the Group recorded revenue of RM52.10 million, representing an increase of 4.18% compared to RM50.01 million in the preceding quarter. The higher revenue was mainly driven by stronger sales from Malaysia operations, coupled with a marginal increase in contributions from the Singapore and Indonesia operations during the current quarter under review

The Group recorded a PBT of RM20.98 million and PAT of RM15.37 million in the current financial quarter ended 31 August 2025, representing a slight decrease of RM0.39 million or 1.82% in PBT and RM0.88 million or 5.42% in PAT compared to the immediate preceding quarter ended 31 May 2025, which recorded a PBT of RM21.37 million and PAT of RM16.25 million. The decline in PBT and PAT was due to the increase in payroll expenses, other operational costs and initial costs related to ongoing expansion initiatives of the Group.

**B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)**

**B3. Prospects**

Alpha IVF Group is well-positioned to support the growing demand for Assisted Reproductive Services (“ARS”), driven by global demographic trends, including declining birth rates and changing lifestyle choices that lead to delayed parenthood. The Group’s strategy is to strengthen its domestic market leadership while expanding its regional presence in key international markets.

In Malaysia, declining birth rates and strong government support for fertility care present opportunities for expansion. Building on the country’s position as a leading medical tourism hub, the Group is establishing two additional IVF centres in Sabah and Johor, targeted to commence operations in the financial year ending 31 May 2026 (“FYE2026”).

Regionally, the Group is deepening its footprint in Indonesia, a market presenting a significant opportunity supported by its large population and strong cross-border patient flow. In addition to its two existing satellite clinics in Jakarta and Surabaya, the Group has plans to launch two more satellite clinics across Indonesia by the end of FYE2026. Furthermore, the Group had on 30 September 2025 signed a land lease agreement with state-owned entity PT Hotel Indonesia Natour to facilitate the development of a full-fledged IVF centre in the Sanur Special Economic Zone, Bali.

Simultaneously, the Group is strategically entering the Philippines to capitalise on a promising, yet underserved market. The Group is planning to establish two full-fledged IVF centres in Manila and Tuguegarao to address the rising need for specialized reproductive care.

By advancing its domestic initiatives and executing its strategic regional expansion across Malaysia, Indonesia, China, and the Philippines, the Group is actively reinforcing its market leadership and driving sustainable long-term growth.

**B4. Profit forecast or profit guarantee**

The Group did not issue any profit forecast or profit guarantee in any public document in respect of the interim financial reporting period under review.

**B5. Status of corporate proposals**

There were no corporate proposals announced but not completed as at the date of this interim financial report.

**B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF  
BURSA MALAYSIA SECURITIES BERHAD (CONT'D)**

**B6. Income tax expense**

	<u>CURRENT QUARTER ENDED</u>		<u>CUMULATIVE PERIOD ENDED</u>	
	31.8.2025	31.8.2024	31.8.2025	31.8.2024
	RM'000	RM'000	RM'000	RM'000
Income tax expense				
- Current year	5,613	4,059	5,613	4,059
- Prior year	-	-	-	-
Deferred tax expense				
- Current year	-	(2)	-	(2)
- Prior year	-	-	-	-
	<u>5,613</u>	<u>4,057</u>	<u>5,613</u>	<u>4,057</u>
Effective tax rate (%)	27%	21%	27%	21%

The Group's effective tax rate for the current quarter and financial period ended 31 August 2025 was higher than the statutory tax rate of 24%, mainly because of deferred tax assets were not recognised on temporary differences arising from unused tax losses in certain subsidiaries that have not yet commenced business operations.

**(THE REST OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK)**

**B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF  
BURSA MALAYSIA SECURITIES BERHAD (CONT'D)**

**B7. Utilisation of Proceeds from the IPO**

The gross proceeds raised from the Public Issue is RM116.64 million and the status of the utilisation of proceeds as at 31 August 2025 is as follows:

Details of utilisation <sup>(1)</sup>	Initial	After variations <sup>(2)</sup>	Utilised as at 31 August 2025	Unutilised IPO Proceeds	Timeframe for utilisation
	RM'000	RM'000	RM'000	RM'000	
Establishing new medical centres, satellite clinics and sales representative offices as follows:-					
(a) Two (2) specialist centres in Malaysia	32,000	21,400	(5,855)	15,545	
(b) Two (2) specialist centres in Indonesia	17,100	17,100	(18)	17,082	
(c) Four (4) satellite clinics in Indonesia	7,000	6,200	(2,830)	3,370	
(d) One (1) specialist centre in Laos / Cambodia	13,900	-	-	-	
(e) Two (2) sales representative offices in China	2,800	2,400	(1,411)	989	Within 36 months from the listing date
Expansion and upgrade of existing medical centres, facilities and corporate office	15,700	13,670	(3,968)	9,702	Within 36 months from the listing date
Establishment / acquisition of medical centres, satellite clinics and sales representative offices in Asia including, but not limited to, Malaysia, Indonesia, Philippines and China	-	27,500	(4,800)	22,700	Within 36 months from 21 August 2024
Research and development	2,200	2,200	(1,195)	1,005	Within 36 months from the listing date
General working capital	17,140	17,370	(7,570)	9,800	Within 36 months from the listing date
General corporate purposes	2,600	2,600	(1,026)	1,574	Within 36 months from the listing date
Defraying the listing expenses	6,200	6,200	(6,200) <sup>(3)</sup>	-	Within 1 month from the listing date
<b>Total</b>	<b>116,640</b>	<b>116,640</b>	<b>(34,873)</b>	<b>81,767</b>	

**B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD (CONT'D)**

**B7. Utilisation of Proceeds from the IPO (Cont'd)**

**Notes:**

- (1) The utilisation of proceeds as disclosed above should be read in conjunction with the Prospectus dated 1 March 2024 in relation to its IPO and the announcement on variations of utilisation of IPO proceeds dated 21 August 2024.
- (2) The Company had varied the utilisation of IPO Proceeds to reallocate a total of RM27.73 million or approximately 23.77% for (i) establishing new medical centres, satellite clinics and sales representative offices and (ii) expansion and upgrade of existing medical centres, facilities and corporate office to (i) establishment / acquisition of medical centres, satellite clinics and sales representative offices in Asia including, but not limited to, Malaysia, Indonesia, Philippines and China as well as (ii) general working capital.
- (3) The listing expenses of RM5.89 million have been fully paid and the balance of RM0.31 million will be used as working capital of the Group. The Company has since fully utilised the RM0.31 million for working capital purpose.

**B8. Group Borrowings and Debt Securities**

There were no group borrowings and debt securities as at 31 August 2025 and 31 May 2025.

**B9. Material Litigation**

There was no material litigation involving the Group as at 31 August 2025.

**B10. Dividend Proposed or Declared**

Save as disclosed in item A8, there were no other dividends has been proposed and declared as at the date of this report.

**B11. Earnings per share**

The basic earnings per share ("EPS") is calculated by dividing the profit for the period attributable to Owners of the Company by weighted average number of ordinary shares of the Company during the financial period as follows:

	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
	31.8.2025	31.8.2024	31.8.2025	31.8.2024
Profit attributable to Owners of the Company (RM'000)	15,280	14,381	15,280	14,381
Weighted average number of ordinary shares ('000)	4,860,000	4,860,000	4,860,000	4,860,000
Basic/Diluted EPS (sen)	0.31	0.30	0.31	0.30

**B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF  
BURSA MALAYSIA SECURITIES BERHAD (CONT'D)**

**B12. Notes to the Condensed Statement of Profit or Loss and Other Comprehensive Income**

	<u>CURRENT QUARTER ENDED</u>		<u>CUMULATIVE PERIOD ENDED</u>	
	31.8.2025	31.8.2024	31.8.2025	31.8.2024
	RM'000	RM'000	RM'000	RM'000
Profit before taxation is arrived at after charging/(crediting):				
Depreciation of equipment	932	600	932	600
Depreciation of right-of-use assets	1,188	692	1,188	692
Fair value gain on short-term investments:				
- money market funds	(213)	-	(213)	-
- unit trust funds	(44)	-	(44)	-
Dividend income from a short-term investment	(2)	-	(2)	-
Interest income	(1,283)	(1,524)	(1,283)	(1,524)
Interest expenses	414	256	414	256
Equipment written off	5	-	5	-
(Gain)/Loss on disposal of equipment	(36)	#	(36)	#
Unrealised loss in foreign exchange	560	-	560	-
Realised (gain)/loss in foreign exchange	(100)	17	(100)	17

**Note:**

# – Less than RM1,000.

**B13. Approval of Interim Financial Report**

The interim financial report as set out above was authorised for issuance by the Board of Directors on 28 October 2025.